Zacks Research Comments on Eli Lilly and Company’s Q1 2025 Earnings (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Equities research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Eli Lilly and Company in a research note issued on Monday, August 26th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $4.72 for the quarter, down from their previous forecast of $4.77. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $13.79 per share.

Several other equities analysts have also weighed in on the company. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, August 19th. Argus raised their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Finally, Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $961.76.

Eli Lilly and Company Price Performance

NYSE LLY opened at $954.48 on Tuesday. Eli Lilly and Company has a fifty-two week low of $516.57 and a fifty-two week high of $972.53. The stock’s 50-day moving average is $887.63 and its two-hundred day moving average is $816.72. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The firm has a market cap of $907.14 billion, a P/E ratio of 140.57, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Institutional Trading of Eli Lilly and Company

A number of institutional investors have recently bought and sold shares of LLY. Norges Bank acquired a new stake in Eli Lilly and Company during the 4th quarter worth $5,992,890,000. Swedbank AB acquired a new stake in Eli Lilly and Company during the 1st quarter worth $932,797,000. Sapient Capital LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth $682,139,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares during the period. Finally, Wulff Hansen & CO. grew its holdings in Eli Lilly and Company by 90,438.0% during the 2nd quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after acquiring an additional 936,033 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the transaction, the executive vice president now owns 25,428 shares in the company, valued at approximately $20,835,194.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,120,089 shares of company stock worth $990,278,343. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.